Our business in numbers*
value of life science portfolio
members of the investment team
investment team with PhDs/MDs
portfolio company board seats
Building the next generation of global leaders
We do this by founding, building and funding companies to turn exceptional science into transformational treatments to patients in areas of high unmet need.
A strong sense of culture and social purpose
We invest to extend and enhance human life.
We have a strong, entrepreneurial culture, where everyone takes personal ownership for delivering Syncona’s mission. Our culture is underpinned by our values.
Driving value creation through strategy
We take a long-term approach to building leading life science companies, focusing on maximising value through the cycle. Our fundamental view is that value creation in life science comes by taking products into late development, product approval and, in some cases, beyond.
A team of experts
The life sciences investment team members have deep technical scientific backgrounds, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch.
“Our strategy is clear. Syncona is building a sustainable, diversified portfolio of 15-20 companies over a rolling 10-year period.”
Also in this section
Our differentiated model
We found, build and fund companies around exceptional science in areas of high unmet medical need, where there is potential to take product to market.
Rapid translation of scientific research
Our platform enables the rapid translation of scientific research into companies with the potential to be global leaders.
A data-driven investment process
Our data driven investment process leverages the team’s significant expertise.
Founded to make a difference
Syncona was co-founded in 2012 by the Wellcome Trust, the premium charitable funder of life sciences in the UK. The business was set up to address the lack of long-term funding in UK life science by creating globally competitive, sustainable companies.
Latest company updates
*Unless stated all financials at 30 September 2021